Management of bleeding and procedures in patients on antiplatelet therapy by Swan, D. et al.
This is a repository copy of Management of bleeding and procedures in patients on 
antiplatelet therapy.




Swan, D., Loughran, N., Makris, M. orcid.org/0000-0001-7622-7939 et al. (1 more author) 
(2019) Management of bleeding and procedures in patients on antiplatelet therapy. Blood 
Reviews. ISSN 0268-960X 
https://doi.org/10.1016/j.blre.2019.100619





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
Management of Bleeding and Procedures in Patients on Antiplatelet Therapy 
 
 
Dawn Swan 1 
Niamh Loughran 2 
Mike Makris 3, 4 





1Department of Haematology, University Hospital Galway, Galway, Republic of Ireland 
2 Department of Haematology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, 
United Kingdom. 
3 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. 
4 Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK. 
 
 
Corresponding author: Dr Dawn Swan 
Phone : +353 838079472 
Email : dawnswan123@gmail.com 
 
 










Antiplatelet medications have long been the mainstay for secondary prevention in cardiovascular disorders. 
More recently, with the advent of coronary stents, there has been an increased use of more potent antiplatelet 
agents to prevent stent occlusion. Since these drugs are antithrombotic, it is not unusual for them to be 
associated with serious bleeding, particularly intracranial and gastrointestinal haemorrhage. There are no 
robust guidelines on how to manage these clinical situations, although there have been some important studies 
published recently in this area. Similarly, there is very limited evidence on how to manage urgent surgery in 
patients receiving these medications. In this review, we provide updated guidance on the management of 






















Cardiovascular disease remains the leading cause of morbidity and mortality worldwide although mortality in 
the Western world is falling. A 68% decline in mortality in the UK observed from 1980 to 2013, has been largely 
attributed to public health measures and risk factor control, alongside a seven-fold increase in rates of 
percutaneous coronary intervention (PCI) from 1993 to 2013 (1). Since the widespread uptake of PCI, more 
and more patients are treated with single or dual anti-platelet therapy (APT) to prevent stent thrombosis. Use 
of drugs which prevent platelet aggregation, is associated with an increased risk of bleeding, which range from 
serious such as intracranial haemorrhage or gastrointestinal bleeding to minor skin bruising. Also, the 
subgroup of patients who require APT, due to their increased age and presence of comorbidities, also have 
an increased need for surgical interventions. It has been estimated that 4-8% of patients who have had a 
coronary stent inserted will require major surgery within one year of stent placement (2). Herein a dilemma 
arises regarding appropriate peri-operative management of their APT. On one hand, evidence has shown that 
continuation of APT peri-operatively can increase the frequency of procedural bleeding (3) whilst 
discontinuation can increase the risk of cardiovascular events (4, 5). This review aims to examine the risks 




The anti-platelet agents and their mechanism of action  
 
The most frequently encountered anti-platelet therapies are aspirin, the ADP-inhibitors clopidogrel, prasugrel 
and ticagrelor, and occasionally the GP IIb/IIIa inhibitors (summary in Table 1).  
 
Aspirin 
Aspirin irreversibly inhibits cyclo-oxygenase (COX)-1 and -2 (6-8), preventing production of thromboxane A2 
(TXA2) from arachidonic acid and thereby blocking TXA2-induced platelet aggregation and stimulation of 
further TXA2 release.  
 
ADP inhibitors (Thienopyridines) 
 ADP (adenosine diphosphate) binding to the P2Y12 and P2Y1 receptors is necessary for the subsequent 
exposure of GP IIb/IIIa and fibrinogen-mediated platelet-platelet interactions (9). There are three P2Y12 
inhibitors currently in routine use; clopidogrel, prasugrel and ticagrelor. Clopidogrel and prasugrel must be 
metabolised to become active whilst ticagrelor is already in its active state. Clopidogrel and prasugrel inhibit 
the P2Y12 receptor irreversibly whereas ticagrelor binds reversibly (10). Cangrelor is an intravenous, direct-
acting, reversible ATP (adenosine triphosphate) analogue with a high affinity for the P2Y12 receptor.  
 
GPIIb/IIIa inhibitors 
GPIIb/IIIa is critical for fibrinogen-mediated platelet binding to allow formation of the platelet aggregate. The 
available GP IIb/IIIa inhibitors are abciximab, eptifibatide and tirofiban, which are all administered via 
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intravenous infusion, due to their short half-lives. Abciximab is a chimeric (mouse/human) monoclonal antibody 
that binds to platelets, whereas tirofiban and eptifbatide are small molecule inhibitors (11). Abciximab is 
associated with a transient mild thrombocytopenia in 2-3% of patients which is of no clinical significance, but 
may also cause a severe thrombocytopenia in <2% due to the presence of preformed antibodies against 
murine IgG (12). It should be noted however, that abciximab (ReoPro, Janssen) was withdrawn from the market 
in 2019 due to interrupted production at a third-party manufacturing site. Eptifibatide and tirofiban, unlike 
abciximab, block the RGD (arginine-glycine-aspartate) sequence within GPIIb/IIIa, preventing the crucial 
association between fibrinogen and von Willebrand factor (13).  
 
PAR antagonists 
Protease activated receptor-1 and -4 (PAR-1 and PAR-4) are the two thrombin receptors expressed on the 
platelet surface. One PAR-1 antagonist, vorapaxar, has been approved by the FDA for secondary prevention 
in patients with prior myocardial infarction or peripheral arterial disease, but has not gained European approval 
and is not available for clinical use in the European Union (14).  
 
 
Managing intracranial haemorrhage in patients on anti-platelet therapies 
 
Incidence 
Spontaneous ICH accounts for approximately 6-20% of all strokes (15), and at thirty days carries a mortality 
of over 40%. Size of haematoma and expansion of the bleed are strongly associated with worse outcomes 
(16). Whether concurrent APT has a significant impact on the overall morbidity and mortality is controversial, 
with conflicting results in spontaneous ICH and traumatic brain injury (17). Observational studies have 
identified an association between aspirin use and development of cerebral microbleeds, which are known to 
increase the risk of spontaneous ICH. Recently, Qiu et al. reviewed nearly 21,000 cases of cerebral 
microbleeds from 37 studies. They found that aspirin use was associated with an increased occurrence of 
lobar microbleeds, and that ICH rate was higher amongst those with cerebral microbleeds than without (18). 
Lobar bleeds have a higher recurrence rate, worse outcome, and are more commonly seen in anticoagulated 
patients, than bleeds affecting deep cortical structures (19). In patients anticoagulated with a vitamin K 
antagonist or direct oral antagonist following thromboembolic stroke, the recent CROMIS-2 study has shown 
that presence of cerebral microbleeds correlated far better with subsequent risk of ICH than the HAS-BLED 
scoring system, with rate of symptomatic ICH reported at 9.8/1000 patient years for those with cerebral 
microbleeds versus 2.6/1000 patients years in those without (20). The ongoing ASPREE-NEURO study, a 
prospective placebo-controlled cohort study in which patients are randomized to low-dose aspirin or placebo, 
and followed up by MRI to identify development of cerebral microbleeds and subsequent stroke, may provide 
more information for patients on aspirin (21). Most of the current data on ICH relates to aspirin and clopidogrel 
use. The TRITON-TIMI 38 trial of prasugrel with aspirin versus clopidogrel with aspirin reported an increase in 
life-threatening bleeding from 0.9% to 1.4% in the prasugrel arm, associated predominantly with prior 
cerebrovascular disease (22). The PLATO trial compared ticagrelor with clopidogrel. Major bleeding rates were 
unchanged but ICH was more common in ticagrelor-treated patients, hence previous ICH is a recommended 
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contraindication to ticagrelor administration (23). The GP IIb/IIIa inhibitors provide very potent platelet inhibition 
but have short half-lives and in the majority of cases of bleeding may be managed by simply stopping drug 
administration (17). At the other end of the spectrum, the PAR-1 inhibitor vorapaxar has such a long half-life 
(5-13 days) (14) that platelet transfusion would be futile, and hence is contraindicated in patients at high risk 
of ICH.  
 
Surgically managed 
Given the lack of agreement as to the importance of antiplatelet agents in spontaneous and traumatic ICH, it 
is unsurprising that optimal management of these patients is also unclear. For patients who require surgical 
management of bleeds, the general consensus is to provide supportive platelet transfusion (17). This 
recommendation is based primarily upon the results of a single randomized controlled trial of 780 patients 
undergoing craniotomy and haematoma evacuation. Patients who had recently taken aspirin and had evidence 
of platelet inhibition on platelet aggregometry were randomised to no platelets, one pool pre-surgery, or one 
pool pre- and one after 24 hours. The transfused arms had significantly reduced rates of ICH recurrence (14% 
versus 35%) and mortality (15.5% versus 34.2%) with improved six-month disability scores. Those patients 
with evidence of aspirin-resistance were not transfused, and had outcomes similar to aspirin-naïve individuals 
(24).   
 
Non-surgically managed 
The available evidence is even more conflicting for spontaneous bleeds and traumatic ICH not planned for 
surgical intervention. One small prospective study reviewed 45 patients with acute ICH, reduced platelet 
activity on presentation (using the VerifyNow system) and subsequent platelet transfusion. They found that 
transfusion within 12 hours was associated with a smaller haemorrhage size on follow-up and improved 
functional outcomes at three months (25). However, the PATCH study, a larger randomised controlled trial of 
190 adults taking anti-platelet agents with spontaneous ICH found platelet transfusions were inferior to 
standard care, with a higher number of adverse events in patients in the platelet transfusion group (26). A 
more recent report of patients with traumatic ICH reviewed the effect of timing of transfusion. Patients taking 
pre-injury aspirin received one pool of platelets, and those on clopidogrel received two. Progression of 
haematoma was significantly associated with subdural bleeds and reduced conscious level on presentation, 
with no significant difference as to whether platelets were transfused within four hours of presentation. This 
finding could be explained by the presence of active drug metabolites in the circulation in the earlier time-
frame, as investigators were unable to obtain the exact time of the last APT consumption. However, the degree 
of benefit provided by the platelet transfusions themselves could not be ascertained due to lack of a control 
non-transfused arm (27).  
 
Role of drug therapies 
The role of DDAVP in the setting of ICH has been examined in a handful of small, uncontrolled studies. There 
is some suggestion, but no robust evidence that DDAVP may temporarily improve platelet function providing 
some additional benefit (28, 29), and its use may be considered in this setting. There are rare reports of 
cerebrovascular or cardiac thrombotic events associated with DDAVP use however, so a judicious review of 
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comorbidities is recommended prior to administration (30, 31). DDAVP has been associated with 
hyponatraemia secondary to water retention. This risk is minimized by adherence to recommendations 
regarding fluid intake during treatment (32). Intracranial haemorrhage, particularly subarachnoid haemorrhage 
may also cause hyponatraemia, either due to SIADH (syndrome of inappropriate antidiuretic hormone) or 
cerebral salt wasting. In certain cases, vasopressin antagonists have been used to treat this condition (33). 
Evidence of hyponatraemia (serum sodium <135 mmol/l) should therefore warrant caution prior to DDAVP 
administration, but there are no formal recommendations to guide this practice.  Recombinant factor VIIa 
increases thrombin generation at the platelet surface improving haemostasis. Its use has been reported in 
acute ICH but extreme caution is advocated, as the prothrombotic nature of rFVIIa may lead to adverse events 
in patients with pre-existing hypercoagulable states which required the antiplatelet medications (34).  
 
Reintroduction of antiplatelet agents 
 
There is very little data regarding whether to restart antiplatelet medications in patients who have suffered an 
ICH, and even less that addresses the issue of timing. The RESTART trial followed 537 patients post-ICH, half 
of whom restarted antiplatelet medications and the other half did not. At a median two years follow-up, 4% of 
the anti-platelet group had a recurrence of ICH versus 9% of the no anti-platelet group, and there was also no 
significant difference in rates of vascular adverse events (35). Effect of site of haemorrhage, surgical or non-
surgical management, thrombotic risk factors and indication for anti-platelet agents on risk of recurrence and 
adverse cardiovascular events is not known, nor can we glean any information regarding the time at which 
antiplatelet medications should be restarted from this study. Reintroduction of antiplatelet agents at least 
seems likely to be safe in selected patients, but further information is required before formal recommendations 
can be made.  
 
Summary 
It is likely, although not fully established, that concomitant APT use may worsen outcomes in spontaneous and 
traumatic ICH. Platelet transfusion is recommended in patients planned for neurosurgical intervention, 
although the optimal time of delivery and dose required is uncertain. Evidence for platelet transfusion in the 
non-surgical setting in patients taking APT is less convincing with notable reports of worsened outcomes post 
platelet transfusion (26), and platelet transfusion is therefore not routinely recommended in these patients. The 
value of adjunctive therapies such as DDAVP and rFVIIa is unproven and associated with considerable risks 
requiring careful patient selection.  
 
 
Managing gastrointestinal haemorrhage in patients on anti-platelet therapies 
 
Gastrointestinal haemorrhage (GIH) is a common clinical presentation with or without concomitant antiplatelet 
medications (36). The UK incidence is around 50-190/10,000 patients per year (37, 38). A meta-analysis of 14 
trials reported that low-dose aspirin (75-300mg) was associated with a relative risk of major GIH of 
approximately 2, with a modest annual absolute increased rate of 0.12%/year, which was slightly less for 
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single-agent clopidogrel (39). In terms of dual APT, aspirin plus clopidogrel confer reported rates of 1.3%-4.6% 
per year (40-42), whereas the newer P2Y12 inhibitors, prasugrel and ticagrelor, are associated with increased 
rates of GI bleeding compared to clopidogrel (major bleeding in 2.4% vs 1.8% prasugrel vs clopidogrel, non-
coronary artery bypass graft-related major bleeding 4.5% vs 3.8% ticagrelor vs clopidogrel) (22, 23). GI 
haemorrhage is associated with increased risk of further ischaemic events and mortality (43) which may be 
related to premature cessation of antiplatelet medications alongside a prothrombotic state induced by bleeding 
(44). 
 
Early endoscopic control of bleeding can prevent surgical intervention, reduce inpatient stay, and is 
recommended for patients suspected to have upper GI haemorrhage (45).  Proton pump inhibition (PPI) is 
recommended in all patients unless contraindicated, as it has been shown to improve outcomes in both the 
acute bleed (46) and prevention of re-bleeds in patients continuing both single-agent and dual-agent 
antiplatelet therapy (47, 48). Choice of PPI should take the degree of inhibition of CYP2C19 into consideration, 
particularly for patients taking clopidogrel, which requires metabolism by this enzyme amongst others into its 
active form. Meta-analyses have reported an excess of adverse cardiovascular outcomes in patients receiving 
DAPT alongside PPIs (49). Omeprazole has been shown to reduce platelet reactivity ex vivo in the Omeprazole 
CLopidogrel Aspirin (OCLA) study (50), however in patients receiving omeprazole alongside clopidogrel in the 
COGENT trial (Clopidogrel and the Optimisation of Gastrointestinal Events Trial), there was no significant 
increase in cardiovascular events noted at a median duration of follow-up of 110 days (51). Pantoprazole and 
esomeprazole were not shown to affect platelet reactivity in patients undergoing PCI (52). Lansoprazole was 
shown to have no effect on platelet inhibition in healthy subjects receiving prasugrel, with some impairment of 
inhibition in those taking clopidogrel identified (53). There is therefore no definitive evidence of superiority of 
one PPI over another. Omeprazole certainly affects platelet inhibition, however this has not been clearly 
demonstrated to alter outcomes. Pantoprazole and esomeprazole also appear to be safe choices from the 
available evidence.   
 
Discontinuation and reintroduction of the patient’s antiplatelet agents has been discussed in a recent review 
by Scott et al. (36). For cases where endoscopic control has been achieved and recurrent bleeding risk is low, 
antiplatelet agents may be safely continued throughout. For patients on single-agent therapy with a high-risk 
of rebleeding, the antiplatelet therapy may be held for 3-7 days. For patients on dual APT, particularly following 
recent cardiac stent insertion, it is recommended to continue aspirin and discuss reintroduction of a second 
agent with a cardiologist.  
 
In terms of platelet transfusions for acute GIH the limited evidence, is largely unfavourable. A retrospective 
review of approximately 400 patients with antiplatelet-associated GI bleeding found increased rates of 
cardiovascular events (23% versus 13%) and a significantly increased mortality rate (7% versus 1%) amongst 
platelet transfused patients compared to controls. However, the transfused patients had more severe 
presentations but platelet transfusions have not been shown to provide significant benefit (54). Based on these 
results, the 2018 Asian Pacific Gastroenterology guidelines do not recommend platelet transfusions (55), 
8 
 
whereas the American Society of Gastroenterology Guidelines include transfusion as an option in severe cases 
(56). 
Summary 
APT lead to a small but significantly increased risk of GIH. Acute management is with endoscopic intervention 
alongside supportive care with PPIs, and H. pylori eradication where appropriate. Antiplatelet drugs may 
require temporary cessation, but platelet transfusion is unlikely to be beneficial in most cases. 
 
Managing anti-platelet therapies prior to elective surgery 
 
The peri-operative management of APT is complex, and several factors must be considered before a 
management plan is formulated. The key factors are the indication for APT use and the type of surgery with 
its associated bleeding risk (57). Assessment of thrombotic risk should include the severity, elapsed time since 
the ischaemic event(s) and the type of stent inserted (58). In terms of bleeding risk, in addition to likelihood of 
bleeding from specific procedures, other relevant factors characteristic to the individual should also be taken 
into account (Table 2). 
 




It was common practice to withhold aspirin for 5-7 days prior to major surgery but this is no longer 
recommended for most cases. A comprehensive systematic review by Burger et al. found that continuation of 
aspirin increased the rate of bleeding complications by 1.5-fold but did not increase the severity of bleeding 
complications (59).  Similarly, a case study by Dacey et al. concluded that there was no increase in the amount 
of bleeding requiring transfusion when aspirin was continued throughout surgery (60). With regards to cardiac 
surgery, aspirin continuation increased post-operative bleeding and transfusion requirements with no effect on 
mortality, re-exploration rate or peri-operative myocardial infarction (61). The value of aspirin in reduction of 
thrombotic events has however been questioned by some recent studies. The POISE-2 trial randomised over 
10,000 patients requiring non-cardiac surgery who were at risk of vascular complications between aspirin at 
100mg or placebo. There was no difference in the primary outcome of death or non-fatal MI at 30 days, but 
increased bleeding in the aspirin group (major bleeding in 4.6% versus 3.8% of patients) was seen (62). The 
Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial also compared administration of 
100mg aspirin versus placebo on the day of surgery in coronary artery bypass grafting patients (CABG). No 
difference in thrombotic or bleeding complications was seen between the groups. From these studies, it seems 
likely that discontinuation of aspirin in high bleeding risk patients is safe, however it should be noted that the 
patients in the ATACAS trial were either not taking aspirin originally, or had stopped 4 days prior to surgery, 
so results do not truly reflect discontinuation vs. continuation of aspirin (63).  In comparison, bleeding fatalities 
were reported following intracranial and prostatectomy surgery in patients receiving aspirin (59). If aspirin does 
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require discontinuation, no longer than 8-10 days was suggested by a meta-analysis in which the average time 
from cessation of aspirin to the development of adverse thrombotic events, particularly ACS, was 10.7 days 
(4). Adequate recovery of platelet function for haemostasis usually occurs within approximately 3 to 5 days 
(64-66), and may be faster in patients with high platelet turnover rates, so discontinuation for more than 5 days 
is not warranted in any case (67).   
 
Current recommendations for patients taking aspirin as secondary prophylaxis are: 
 In patients who require elective non-cardiac, or cardiac surgery- aspirin should be continued (57) (68). 
 For surgeries with much higher bleeding risks such as neurosurgery, aspirin should be discontinued 5 
days pre-operatively as per the French working group on perioperative haemostasis (GIHP) in 




P2Y12 inhibitors  
Careful consideration is required for higher-risk patients on these drugs, including those who require dual anti-
platelet therapy (DAPT) for secondary prevention following ACS or pre- and post-PCI with stent insertion.  
The peri-operative period poses a particular challenge to patients receiving DAPT, as the proinflammatory and 
prothrombotic state induced by surgery increase the thrombosis risk alongside the procedure-related bleeding 
risk (69). DAPT is critical in the prevention of stent thrombosis and many studies have found that premature 
discontinuation of DAPT before complete endothelialisation of the stent can result in major adverse coronary 
events (MACE) (70, 71). Concerns have been raised regarding a possible hypercoagulable state following 
discontinuation of anti-platelet agents, particularly clopidogrel (72), however the randomised controlled Platelet 
Activity after Clopidogrel Termination (PACT) study found no evidence of increased platelet activity following 
clopidogrel cessation, measured by several different techniques (73). Studies comparing bare-metal stents 
(BMS) with first generation drug-eluting stents (DES) (paclitaxel or sirolimus) identified a higher risk of in-stent 
thrombosis in DES-managed patients. The newer second generation DES (zotarolimus, ridaforolimus and 
everolimus) confer a lesser risk, whereas bioresorbable stents have a higher incidence of in-stent thrombosis 
reported, particularly during the first 30 days (68, 74). The particular stent in each patient therefore requires 
consideration, but in recent times, the majority of stents inserted are second generation DES.  
A number of registries have reported that the non-cardiac surgery-related thrombosis risk in DES-PCI-treated 
patients plateaus after 3-6 months (68). A North American registry paired two cohorts of stented patients, one 
undergoing non-cardiac surgery within 24 months of stent placement, and one not. Risk of adverse cardiac 
events was increased in the first 30 post-operative days, irrespective of stent type. The incremental risk for MI 
decreased from 5% immediately after stent insertion to 2% at 1 year (75). Whilst stent type did not have a 
significant impact on risk, major cardiac events were more common in patients who were stented for MI (7.5%) 
versus unstable angina (2.7%) and elective revascularisation not associated with acute coronary syndrome 
(ACS) (2.6%). In the MI patients, the risk was significantly increased within the first 3 months following stent 
insertion (76). A Danish registry compared patients with DES-PCI-treated coronary artery disease (CAD) 
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undergoing a surgical procedure within 12 months of stent-placement with a control group undergoing the 
same procedure without a diagnosis of CAD. They found that risk of MI and cardiac-death was increased in 
the PCI group, but only for the 1st month post-PCI (77).  
When discontinuing DAPT, the time at which it is safe to discontinue the available P2Y12 inhibitors is variable. 
With respect to cardiac surgery, in patients undergoing CABG within the CURE trial, discontinuation of 
clopidogrel from DAPT 5 days pre-operatively was not associated with increased bleeding complications (78). 
Platelet inhibition takes longer to resolve following discontinuation of prasugrel than clopidogrel (approximately 
7-10 days compared with 7 for clopidogrel) (79)). This fact coupled with the increased rates of bleeding seen 
with prasugrel in the TRITON-TIMI trial (22) have led to recommendation of a longer time interval of 7 days 
pre-operatively by both the ESC and GIHP guidelines (67, 68). Ticagrelor was initially recommended for 
discontinuation 5 days pre-operatively, however this has been reduced to 3 days within the latest ESC 
guidelines (68), but remains at 5 days in the GIHP guidelines (67). A Swedish Nationwide study assessed 
CABG-related bleeding episodes in relation to timing of P2Y12 inhibitor discontinuation. They found no 
significant difference in bleeding rates between ticagrelor-treated patients in whom the drug was discontinued 
either >120 hours pre-operatively or between 72-120 hours, with increased bleeding at <72 hours. Whereas 
the clopidogrel-treated patients had more bleeding episodes if clopidogrel was discontinued between 72-120 
hours compared with >120 hours pre-operatively (80). Another study compared patients undergoing CABG 
treated with DAPT with aspirin and ticagrelor with those receiving aspirin only. Discontinuation of ticagrelor >2 
days pre-operatively was associated with increased rates of platelet transfusion (12.4% versus 3.6%) but not 
increased bleeding (81).  
 
Longer discontinuation may be necessary for the P2Y12 inhibitors in surgeries with unacceptably high bleeding 
risks such as neurosurgical procedures, and transurethral resection of the prostate (58, 82, 83). For patients 
at both high thrombotic and high haemorrhagic risk, bridging may be considered (84-87), whereby the patient’s 
oral ADP receptor antagonist is held 5-7 days pre-operatively, and an intravenous infusion of either a P2Y12 
inhibitor or GP IIb/IIIa antagonist is administered until a few hours before surgery. The BRIDGE trial has shown 
promising results for the P2Y12 inhibitor cangrelor in this context. Patients receiving thienopyridines prior to 
coronary artery bypass surgery (CABG) stopped the thienopyridine 48 hours pre-operatively and were 
randomised to cangrelor or placebo until 6 hours prior to surgery. Cangrelor was shown to effectively maintain 
platelet inhibition without an associated significant increase in bleeding, although it is not presently FDA- or 
EMA-approved for this indication (88). GPIIb/IIIa inhibition has also been tested in a small phase 2 study of 30 
patients with a DES inserted within the past 12 months, at high risk for in-stent thrombosis, who required eye 
or major surgery. Cloipidogrel was discontinued 5 days pre-operatively, with tirofiban commenced after 24 
hours and stopped 4 hours before surgery. There were no thrombotic complications and one case of 
thrombolysis in myocardial infarction (TIMI) minor and 1 TIMI major bleeding episode reported (89).  
 
Taking the above information into consideration, current recommendations are that for patients taking who 
require elective cardiac surgery (57, 58, 67, 68): 
 Aspirin should be continued around the time of surgery. 
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 Ticagrelor should be discontinued 3 days before surgery. 
 Clopidogrel should be discontinued 5 days before surgery. 
 Prasugrel should be discontinued 7 days before surgery. 
 
For patients with a history of recent MI, or who have undergone PCI and stent insertion requiring non-cardiac 
surgery (67, 68):  
 Where possible, surgery should be postponed until at least 6 weeks after a medically managed MI 
(90). 
 Non-cardiac elective procedures should be postponed until completion of DAPT if possible. 
 Non-cardiac elective procedures should be postponed for at least 1 month post-stent insertion 
irrespective of type of stent or indication. 
 Non-cardiac elective procedures should be postponed for up to 6 months in patients at high ischaemic 
risk eg. Who presented with MI, have bifurcating lesions, multiple or overlapping stents, impaired left 
ventricular ejection fraction, renal impairment or diabetes mellitus (91). 
 Patients requiring surgery within 1 month of stent placement may be considered for bridging therapy 
 
Restarting anti-platelets post-operatively 
Two meta-analysis have shown improved outcomes in patients who restart DAPT after CABG compared to 
aspirin alone, without significantly higher rates of major bleeding (92, 93). Rates of thrombosis are high post-
operatively, with significantly more MACE occurring in patients not taking anti-platelet agents (94). The ESC 
has recommended reinstation of DAPT from 24-96 hours post-CABG, and within 48 hours following non-
cardiac surgery (68).  
 
Early resumption of anti-platelets is likely to be more important in patients with more risk factors for ischaemia. 
A risk score such as the DAPT score (see Table 3.) can be used to identify patients at higher risk of thrombotic 
events (95). However, this score was designed to identify patients who may benefit from extended duration 
DAPT treatment, and not for use as a decision aid in when to restart DAPT. Consideration of the patient’s 
bleeding risk is also required in conjunction. Two such bleeding risk scores have been generated from the 
PARIS study, a prospective observational study of patients on DAPT undergoing PCI. Reasons for cessation 
of DAPT included physician-recommended discontinuation, interruption for surgery and disruption due to non-
compliance or bleeding (96). Of note, recent analysis has shown that patients 75 years are more likely to 
have DAPT held than younger patients, but that this is not associated with increased MACE (defined as a 
composite of cardiac death, probable or definite in-stent thrombosis, spontaneous MI or clinically indicated 
target lesion revascularization), whereas disruption of DAPT is associated with increased MACE in patients 
<75 years (97). Younger age has been identified as a risk factor in the DAPT score, and these results also 
suggest that disruption of DAPT may be better tolerated in older patients, highlighting the need for 
management to be tailored to the individual patient.  
 
Current recommendations for restarting DAPT post-operatively are (68): 
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 Clopidogrel, prasugrel or ticagrelor should be recommenced after 24-96 hours post-operatively and 
ideally at <48 hours in those with recent (<6 weeks) PCI or who presented with ACS. 
 
Managing anti-platelet therapies prior to neuraxial anaesthesia 
 
Spinal haematoma is a rare but potentially devastating complication of neuraxial procedures with a reported 
incidence of anywhere between 1/1300-1/200,000 procedures (98). Risk factors for spinal haematoma include 
female gender, advanced age, wider gauge needles/catheters (incidence is higher for epidural than spinal 
anaesthesia), a history of excessive bleeding or bruising, multiple needle passes, and pre-existing bone 
disease such as osteoporosis (99, 100). Aspirin is generally considered safe to use during neuraxial 
procedures. A prospective study in nearly 1000  orthopaedic patients undergoing spinal or epidural 
anaesthesia, of whom approximately one fifth were taking pre-procedure aspirin, reported no increase in blood 
present at the time of needle/catheter placement or withdrawal in the group taking aspirin (100). Similarly, a 
randomized controlled trial of the role of low-dose aspirin for pre-eclampsia found no increase in bleeding 
events post-epidural in the intervention arm (101). Evidence pertaining to the ADP-receptor antagonists in 
neuraxial anaesthesia is sparse, and consequently, most guidelines have historically recommended that these 
drugs be withdrawn approximately a week pre-procedure (57, 102-104). The most recent GIHP 
recommendations are that regional anaesthesia is contraindicated in patients on P2Y12 inhibitors unless 
discontinued 5 days pre-procedurally for clopidogrel and ticagrelor and 7 days for prasugrel (67), in line with 
their recommendations for withdrawal pre-elective surgery, and the latest ESC guidelines do not specifically 
discuss this topic. The American Society of Anaesthesia and Regional Pain Medicine have also recommended 
a 5 day discontinuation period in their 2018 updated guideline (105). They have recommended that patients 
may restart clopidogrel with the neuraxial catheter still in situ for 1-2 days, provided a loading dose has not 
been administered. Ticagrelor and prasugrel have a faster onset of action, so catheter removal prior to 
reintroduction of these agents is mandated. Without a loading dose, ticagrelor and prasugrel may be given 




 If on aspirin monotherapy, this may be continued without interruption. 
 If on dual-antiplatelet therapy, neuraxial anaesthesia should be postponed if possible in line with the 
recommendations for elective surgery. 
 If neuraxial anaesthesia is required, clopidogrel and ticagrelor should be discontinued 5 days pre-
procedure and prasugrel 7 days pre-procedure.  
 For patients taking DAPT, platelet transfusion can be considered in emergency cases and tranexamic 
acid may be used as a haemostatic adjunct. 
 Following removal of neuraxial catheter or needle placement, clopidogrel, prasugrel and ticagrelor 
may be restarted immediately.  





Managing anti-platelet therapies prior to emergency surgery  
When patients on APT need urgent surgical intervention the healthcare team are faced with the dilemma of 
reversing or counteracting the effects of these agents. One strategy is platelet transfusion. In vitro studies have 
found that in platelets treated with clopidogrel and aspirin, normalisation of platelet function is observed after 
the addition of two to three pools of treatment-naïve platelet concentrate (106). However, there are 
uncertainties within this that need to be addressed:  
(i) The optimal platelet transfusion quantity needed to overcome the antiplatelet effects  
(ii) The optimal timing of platelet transfusion relative to the last dose of the anti-platelet agents.  
 
Quantity of platelets transfused 
A unit of 0.7 x 1011 platelets produces an increment of 5000-10,000/l in an average sized adult. Administration 
of 0.7 x 1011/10kg of body weight has been recommended to produce a rise in platelet count of approximately 
40,000/l (107). The average size of a pool of platelets varies between institutions and countries. In the UK it 
is 3 x 1011 (108). Currently there is no definitive guidance on the ideal number of donor platelet units required 
to reverse the anti-platelet effects. Li et al. reported that the reversal of the inhibitory effects of aspirin on 
arachidonic acid (AA)-induced platelet aggregation was much more rapid than the reversal of the inhibition of 
ADP-induced aggregation by clopidogrel (64). This was demonstrated as reversal of aspirin’s anti-platelet 
effect was achieved when mixed samples of aspirin-treated and treatment-naïve platelets contained 30% 
treatment-naïve platelets, compared to 90% required to reverse clopidogrel’s anti-platelet effect.  
Of the ADP-receptor antagonists, available evidence suggests that platelet transfusion can ameliorate the 
effects of clopidogrel more than prasugrel, and that ticagrelor-treated patients gain the least benefit from 
platelet transfusion. For example, transfusion of two pools of platelets to patients taking aspirin and clopidogrel 
restored ADP-induced platelet function determined by the VASP assay (vasodilator-stimulated phosphoprotein 
phosphorylation assay) (109). However, in patients recently administered loading doses of prasugrel and 
ticagrelor post-ACS, a ratio of 60% non-inhibited platelets to patient platelets was required to achieve platelet 
aggregation >40% measured by light transmission aggregometry in those receiving prasugrel, whereas 
platelets from ticagrelor-treated patients remained inhibited at all patient:donor platelet ratios (110). In keeping 
with these studies, the APTITUDE-ACS and APTITUDE-CAGB trials analysed platelet function deficits for 
patients with ACS requiring PCI, or undergoing cardiac surgery, respectively, receiving clopidogrel, prasugrel 
or ticagrelor. Overall, transfusion of platelets improved platelet-dysfunction in clopidogrel-treated patients to a 
greater degree than for prasugrel, which is likely to require a larger dose of platelets for reversal to be effective, 
or ticagrelor, which cannot be effectively reversed by platelet transfusion at all (111). One normal donor pool 
of platelets (apheresis or pooled) should provide more than 50 x 109/l uninhibited platelets, although the 
proportion of these that remain functional will depend on the antiplatelet agent administered, and when the last 
dose was received. One suggestion has been that for patients with evidence of platelet dysfunction, one pool 
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should be adequate for most surgical indications, with two advised for individuals requiring urgent neurosurgery 
or eye surgery (13). 
Another factor that requires consideration is the pro-thrombotic risk of platelet transfusion in these already 
high-risk patients. The risk of thrombotic events rises early after withdrawal of DAPT in high-risk patients and 
further increases after surgery; the infusion of too many donor platelets may contribute to this pro-thrombotic 
state (86). Currently there is very little information regarding the risk of excessive platelet transfusions 
provoking adverse thrombotic events. 
The timing of platelet transfusion 
With regards to the timing of the platelet transfusion, in order for it to be effective there needs to be an absence 
of active anti-platelet metabolites in the patient’s circulation, otherwise the transfused platelets will also be 
inhibited. Aspirin has a short half-life of 15-20 minutes and can be sufficiently cleared after two hours. 
Clopidogrel also has a short half-life of around 30 minutes but clearance of its active metabolites can take 6-8 
hours after ingestion due to variations in absorption and metabolism between individuals (112). Prasugrel and 
ticagrelor also have similar half-lives, and in vitro studies investigating the effect of donor platelet transfusions 
on prasugrel and ticagrelor reversal found that functional platelet recovery was minimal when donor platelets 
were added to blood samples obtained two hours after dosing of prasugrel (113) or ticagrelor (114), in addition 
to aspirin. Zafar et al. therefore concluded that donor platelets should be transfused at least six hours after a 
dose of prasugrel (113). It has been recommended that platelets should ideally be transfused once 3-5 half-
lives have elapsed, however this will clearly not always be possible (17). A more recent study by the same 
group tested the effect of platelet transfusion on patients who had received loading doses of ticagrelor and 
aspirin followed by maintenance for 5-7 days after drug discontinuation. Platelet aggregation (tested by the 
Multiplate and VerfyNow systems) following transfusion reached 59-79% of baseline levels at 24 hours and 
100% at 48 hours, showing the utility of platelet supplementation in ticagrelor-treated patients 1 day post drug 
cessation despite this having essentially no effect during drug-treatment (115). 
A pilot study carried out by Thiele et al. in 14 patients adopted a standardised management plan whereby 
surgery was delayed for 12-24 hours (if possible) after the last dose of aspirin and clopidogrel, then two platelet 
concentrates were transfused 1-2 hours prior to surgery. No observed increases in major bleeding or 
thrombotic complications were reported (112). This approach may therefore be appropriate for patients 
receiving clopidogrel or ticagrelor, but would not be considered safe in prasugrel-treated patients. Results of a 
larger retrospective cohort study in patients on single or dual antiplatelet agents (aspirin and/or clopidogrel 
only) undergoing urgent non-cardiac surgery were recently published in abstract form. All of these patients 
received two pools of platelets pre-operatively with resumption of antiplatelet therapy after 24-48 hours. In 181 
patients, rates of adverse cardiac events (MI, heart failure or rise in troponin T) occurred in 5.5%, with surgery-
related bleeding in 12% (116). Randomised trials have been recommended (116) to further evaluate this 
approach, which could be considered in patients with higher risks of thrombotic episodes in whom prolonged 
discontinuation of therapy is not desirable.  
Non-transfusion strategies  
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Other strategies to help minimise bleeding and transfusion requirements exist. Tranexamic acid has been 
shown to improve the platelet function of those exposed to APT, resulting in a reduction in bleeding and 
transfusion (117). The same has been shown with aprotinin in patients undergoing a coronary artery bypass 
graft. However, there is limited clinical availability of aprotinin and concerns remain about its association with 
increased risk of myocardial infarction and development of renal failure (118). The British Society of 
Haematology guidelines recommend consideration of tranexamic acid to counteract the effect of anti-platelet 
agents after undertaking a risk-benefit assessment, and state that platelet transfusions can be used as an 
additional measure for critical bleeding but should not be used prophylactically (119). Off-label recombinant 
factor VIIa may limit bleeding by reversing the effects of anti-platelet therapy on thrombin generation (120), 
however is a controversial option due to its potential to increase the risk of arterial thromboembolic events, 
and should be considered only as a last resort (121).  
Platelet transfusions do not reverse the effects of ticagrelor. A monoclonal antibody fragment (PB2452) is in 
early clinical development. A phase 1 trial in heathy donors reported reversal of ticagrelor’s antiplatelet effect, 
measured by light transmission aggregometry, a POC P2Y12 test and VASP assay, within 5 minutes, sustained 
for over 20 hours. Future studies are awaited (122). 
Summary 
Suggestions for the management of patients on APT requiring emergency high bleeding-risk surgery are:  
 If on aspirin monotherapy, this can be continued in the majority of cases without further intervention. 
 If on dual anti-platelet therapy: 
o Consider the use of pre-operative intravenous tranexamic acid as a haemostatic adjunct after 
undertaking risk-benefit analysis.  
o If the bleeding risk is thought to be very high, consider platelet transfusions.  
o Do not use platelet transfusions pre-operatively if anti-platelet therapy has not been 
discontinued due to active metabolites still remaining in the circulation. For patients on 
clopidogrel or prasugrel wait at least 6-8 hours after the last dose. Platelet transfusion should 
be considered in ticagrelor-treated patients especially if the last dose was >24 hours prior. 
Ultimately there is no clear guidance on the appropriate dose of platelets required to reverse the effects of 
antiplatelet agents, with risks of excessive transfusion and under transfusion remaining. A possible strategy is 
to rapidly assess a patients bleeding risk and to overcome the transfusion dilemma by the adoption of a strict 
transfusion algorithm incorporating point-of-care testing.  
 
Can point-of-care testing assist in this scenario? 
There is large heterogeneity in response to APT that is not apparent on routine laboratory tests. Several rapid, 
point-of-care (POC) devices have been developed, which may provide a more reliable predictor of an 
individual’s perioperative bleeding-risk, including their degree of platelet inhibition, and at least in theory their 
transfusion-need. POC tests exist which look specifically at platelet function, and inhibition by the various 
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antiplatelet agents. Generally, they are limited in that only one aspect of platelet function is assessed in vitro, 
which cannot fully replicate complex platelet physiology, and direct comparison of different devices is not 
possible due to fundamental differences in the principles of the assays utilised (123). The strengths and 
weaknesses of the various POC tests specific to antiplatelet agents are given in Table 4.  
Various trials have incorporated tests of platelet function in order to assess prediction of future ischaemic or 
bleeding events in various settings in patients taking P2Y12 inhibitors. High levels of platelet reactivity to ADP 
have been shown to correlate well with increased risk of thrombotic events, however the relationship between 
platelet function and bleeding has been less clear (124). The ADAPT-DES study in nearly 9000 individuals 
reported that patients with high platelet reactivity scores despite DAPT with aspirin and clopidogrel were 
significantly more likely to suffer adverse ischaemic events, and less likely to have haemorrhagic complications 
(125). Incorporation of pre-operative ADP-induced platelet aggregometry identified all but one patient with 
severe coagulopathy requiring multiple transfusions during coronary artery bypass grafting with recent 
clopidogrel exposure (126), and use of TEG-PM (thromboelastography with platelet mapping) had similar 
benefit in the randomised prospective TARGET-CAGB trial, which used pre-operative assessment of ADP-
inhibition in patients prior to CABG. Time-to-surgery was stratified according to TEG-PM results with a delay 
of 1 day, 3-5 days, and >5 days in patients with a maximum amplitude (MA) of >50 mm, 35-50 mm, and <35 
mm respectively. Bleeding rates were similar in the various groups and waiting time was significantly reduced 
using this strategy (127).  
A number of groups have incorporated tests of platelet function into ICH management pathways. There are 
concerns however, that platelet transfusion may not reliably affect these results in all cases, whether this has 
clinical relevance for the patient, and indeed, how relevant the results from these tests are in the setting of the 
altered haemostasis seen in patients with brain injury. Several studies have shown improvement in platelet 
reactivity testing following platelet administration in vivo (128-130), whereas others have found the opposite 
(131). Analysis of TEG-PM in 9 patients transfused for antiplatelet-ICH reported good sensitivity but extremely 
poor specificity for identifying the antiplatelet effect of aspirin or clopidogrel, and no significant effect was noted 
following platelet transfusion (132). This may reflect underlying the coagulopathy seen in patients with 
traumatic brain injury (TBI), which has some similarities to the phenomenon of trauma-induced coagulopathy 
(TIC). Patients not taking an ADP antagonist may display significant levels of ADP inhibition, which correlate 
with severity of the insult; the average ADP inhibition reported in TBI with a Glasgow coma scale (GCS) <8 is 
around 90%, compared with 45% if GCS >8, and 15% in healthy controls (133, 134). Transfusion of allogeneic 
platelets may be insufficient to correct this deficit.  
 
Another recent study used platelet reactivity testing to identify COX-2 or ADP-inhibition in patients with 
traumatic ICH suspected to take an antiplatelet agent. Those with evidence of platelet inhibition were 
transfused platelets until the platelet reactivity testing normalised and given a single dose of desmopressin 
(DDAVP). 29% of the cohort had no evidence of inhibition, 92% of which avoided transfusion. Progression of 
haemorrhage occurred in 7%, irrespective of platelet-inhibition or transfusion status. The authors concluded 
that utilizing platelet reactivity testing was a safe means of reducing transfusion rates amongst individuals with 
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traumatic ICH, however, the benefit conferred by platelet transfusion in platelet-inhibited patients cannot be 
deduced from these results (135).  
 
Based on these results, assessment of platelet function pre-operatively using POC tests can aid determination 
of safe timing of urgent or elective procedures, providing reassurance to surgeons that the patient has 
adequate platelet function to proceed, reducing waiting time and length of hospital stay (136), or be used to 
assess whether platelet transfusions are warranted pre-urgent procedures (13). Use in the elective setting has 
good supportive data and numerous groups are also routinely using POC tests to aid management of 
haemorrhagic complications, although issues regarding interpretation of results have been raised, particularly 
with respect to patients with ICH (132). Further evaluation of these algorithms is required, but with refinement 
and standardisation they could be incorporated into the everyday management of patients requiring emergency 
surgery when taking anti-platelet therapy.  
 
Conclusion 
In summary, APT is associated with an increased risk of intracranial and gastrointestinal bleeding. In those 
who develop ICH while on APT, platelet transfusion may be appropriate for planned neurosurgical intervention, 
although the timing and dosing is unclear. In all other scenarios, platelet transfusion may have a detrimental 
effect. APT is associated with GI haemorrhage but platelet transfusion is unlikely to be beneficial, whilst specific 
GI measures are likely to be more effective.  
In patients requiring elective surgery, APT may be discontinued for a specified period if safe to do so, but 
cardiology advice should be sought in those with recently placed coronary stents. Urgent surgery on APT is 
an area that requires more research as no definitive guidance is possible at this stage. Similarly, use of POC 
methods to determine platelet function requires further validation when used as a perioperative tool.  
 
Finally, the recent STOPDAPT-2 randomised study, in which patients undergoing PCI using an everolimus 
second generation DES were randomised between one month of DAPT with aspirin and clopidogrel followed 
by clopidogrel monotherapy and 12 months of DAPT, reported a significant reduction in the primary outcome 
of a composite of cardiovascular death, MI, ischaemic or haemorrhagic stroke, definite stent thrombosis, or 
major or minor bleeding at 12 months, in favour of the short duration DAPT arm. Such results could lead to 
future changes in practice, which may significantly reduce the complexity of peri-operative management of 
these patients (137).  
 
Practice points 
 Patients with intracranial haemorrhage taking APT (antiplatelet therapy) should be transfused platelets 
if planned for neurosurgical intervention but not if receiving medical management only 
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 Patients with upper gastrointestinal haemorrhage on APT do not benefit from platelet transfusions but 
need urgent endoscopic control of bleeding and proton pump inhibition with eradication of H. pylori 
infection if present  
 For elective surgeries on those who are on APT, aspirin may be continued other than for high bleeding 
risk procedures while clopidogrel, prasugrel and ticagrelor should be discontinued several days pre-
operatively 
For emergency surgeries on those who are on APT, transfusion of platelets may be considered in 
patients taking aspirin, clopidogrel or prasugrel if bleeding risk is considered high. Platelet transfusion 
does not reverse the effects of ticagrelor. 
 
Research agenda 
 Role of point of care testing of platelet function in in the peri-operative management of patients 
receiving APT who require emergency surgery, neuraxial anaesthesia or who present with ICH or GIH 
(gastrointestinal haemorrhage) requires further exploration. 
 The optimal dose of platelets required and the timing of transfusion to maximise the benefit in patients 
on APT who develop ICH requiring neurosurgical intervention is yet to be clarified. 
 Development of effective and safe reversal agents for APT is an area of unmet need. 
 
Future considerations 
Antiplatelet drugs have transformed the care of cardiovascular disease. However, with the benefit of reducing 
ischaemic complications comes the risk of bleeding, which may either be spontaneous, or worsened 
procedure-related bleeding. Evidence-based management strategies are required to minimise this risk. Future 
considerations may include i) improved selection of the patients who should receive single and dual APT ii) 
ongoing review of when it is safe to discontinue APT in different patient populations iii) establishing robust 
techniques which can determine adequacy of inhibition of platelet aggregation iv) the role of non-transfusion 
strategies in minimising the bleeding risk of APT and v) confirming the role of specific APT reversal agents in 
clinical practice.  
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